Maqui Berry
Also called maqui, Aristotelia chilensis, Chilean wineberry, Delphinol, MaquiBright, BrightSight.
Best grade C across 8 graded outcomes Botanical Last checked
We earn a commission if you buy through links on this page. It never changes our grades or rankings. How we make money →
The short answer
From 9 sourcesThe best maqui evidence is for dry eyes: in 74 screen workers, 60 mg a day of MaquiBright raised tear production over 4 weeks, and a 20-person Indian trial agreed. Blood-sugar and oxidative-stress results come from small or uncontrolled studies. A 2026 review rated the evidence moderate to very low.
Quick pick
From a partner brand · paid link
Life Extension Tear Support with MaquiBright, 60 mg, 30 Veg Caps
from HerbsPro
Its name matches maquiBright (also sold as BrightSight) standardized extract, one of the forms compared in our Forms table.
Label: 1 capsule: 60 mg MaquiBright maqui berry extract, the dose used in the 74-person dry-eye trial.
Best for trying one bottle: $13.50 one-time (checked Oct 15, 2026).
Every graded outcome on this page
8 rows · line = participants- CGrade CTear production and eye fatigue in screen workers with dry eyesDry eyesn 74
- CGrade COverall evidence across maqui trialsOveralln 12
- DGrade DOxidized LDL and isoprostanes (oxidative-stress markers)Oxidative stressn 42
- DGrade DHbA1c and blood lipids in early prediabetesBlood sugarn 31
- DGrade DHeart rate variability and stress resilienceStressn 30
- DGrade DSigns, symptoms and tear inflammation in dry eye diseaseDry eyesn 20
- DGrade DTear volume and dry-eye quality of lifeDry eyesn 13
- DGrade DAfter-meal blood sugar in impaired glucose regulationBlood sugarn 10
Key facts
- What it is
- A Chilean berry; trials used standardized extracts (MaquiBright, Delphinol) rich in delphinidins25
- Dry eyes (74 people)
- 60 mg a day of MaquiBright raised tear production by 6.4 mm vs placebo over 4 weeks2
- Blood sugar
- Lower after-meal glucose in a 10-person crossover; HbA1c fell in a 31-person study with no control group56
- Certainty
- A 2026 systematic review of 12 trials rated certainty moderate to very low9
What it is
Maqui berry (Aristotelia chilensis) is a Chilean berry rich in delphinidin anthocyanins, sold as standardized extracts such as MaquiBright and Delphinol.
Forms, side by side
2 forms named in our sources. The rest show what our data holds, and say plainly where it holds nothing yet.
Maqui Berry forms compared
2 forms| 2 forms | MaquiBright (also sold as BrightSight) standardized extract | Delphinol standardized extract |
|---|---|---|
| Standardized toMarker compounds, share of extract weight | A berry extract standardized to delphinidins2 | At least 25% delphinidins and 35% anthocyanins5 |
| Absorption in people | Not measured in the cited eye trials; effects were tracked through tear tests.23 | Not measured in the cited trials.56 |
| GI tolerance | No adverse events at 60 mg a day for 4 weeks; blood tests showed no negative findings over 60 days.23 | Well tolerated with no adverse effects at 180 mg a day for 3 months.6 |
| Studied for | Dry eyes and eye fatigue | Blood sugar, lipids, oxidative-stress markers |
- MaquiBright (also sold as BrightSight) standardized extract
- Standardized to
- A berry extract standardized to delphinidins2
- Absorption in people
- Not measured in the cited eye trials; effects were tracked through tear tests.23
- GI tolerance
- No adverse events at 60 mg a day for 4 weeks; blood tests showed no negative findings over 60 days.23
- Studied for
- Dry eyes and eye fatigue
- Delphinol standardized extract
What the human research says
Human trials only, one row per outcome. The form line shows what each trial actually tested. Grades follow our evidence-grading policy.
Trial map
8 graded outcomes, largest study first8 graded outcomes: 6 improved, 2 mixed. The largest, a 2019 randomized trial of 74 people on tear production and eye fatigue in screen workers with dry eyes, found an improvement.
1Tear production and eye fatigue in screen workers with dry eyes
Improved · Grade C · RCT, 74 people, 2019
Japanese adults aged 30 to 60 with eye dryness and at least 4 hours of screen work a day
Dose, result and source| Outcome | Found | People | Study | Who was studied |
|---|---|---|---|---|
| Tear production and eye fatigue in screen workers with dry eyes | Improved | 74 | Grade C · RCT, 2019 | Japanese adults aged 30 to 60 with eye dryness and at least 4 hours of screen work a day |
| Oxidized LDL and isoprostanes (oxidative-stress markers) | Improved | 42 | Grade D · RCT, 2015 | Healthy, overweight and smoking adults aged 45 to 65 |
| HbA1c and blood lipids in early prediabetes | Improved | 31 | Grade D · Open-label trial, 2016 | Adults with newly diagnosed moderate glucose intolerance |
| Heart rate variability and stress resilience | Mixed | 30 | Grade D · RCT, 2023 | Healthy adults (15 per group) |
| Signs, symptoms and tear inflammation in dry eye disease | Improved | 20 | Grade D · RCT, 2023 | Patients with dry eye disease at an eye hospital in Bengaluru, India |
| Tear volume and dry-eye quality of life | Improved | 13 | Grade D · Open-label trial, 2014 | Healthy volunteers with moderately dry eyes |
| Overall evidence across maqui trials | Mixed | 12 | Grade C · Systematic review, 2026 | Adults in 12 clinical trials published 2014 to 2023 |
| After-meal blood sugar in impaired glucose regulation | Improved | 10 | Grade D · Crossover RCT, 2014 | Volunteers with moderate glucose intolerance |
Every graded row
8 rowsShowing 8 of 8 outcomes. Human trials only.
CGrade CTear production and eye fatigue in screen workers with dry eyesDry eyesMore tears, less eye fatigueRCT
n 74 · 2019
Improved Tear production (Schirmer test) rose by 6.4 mm vs placebo (P = 0.005); eye fatigue after screen use (P = 0.047) and bothersome eye symptoms (P = 0.037) improved more than placebo. No adverse events.
- Design
- RCT, n = 74, 2019
- Population
- Japanese adults aged 30 to 60 with eye dryness and at least 4 hours of screen work a day
- Form
- MaquiBright standardized extract
- Dose
- 60 mg a day
- Duration
- 4 weeks
- Source
- Reference 2 · PubMed 31193920 (opens PubMed)
CGrade COverall evidence across maqui trialsOverallPromising for eyes; weak elsewhereSystematic review · 12 studies
n 12 · 2026
Mixed Acute studies consistently lowered after-meal glucose; longer trials showed modest, inconsistent effects on HbA1c and lipids. The most consistent evidence was for tear production and dry-eye symptoms. Certainty ranged from moderate to very low.
- Design
- Systematic review, 12 studies, n = 12, 2026
- Population
- Adults in 12 clinical trials published 2014 to 2023
- Form
- Oral maqui supplements (various extracts)
- Dose
- Varied by trial
- Duration
- Single doses to 3 months
- Source
- Reference 9 · PubMed 42351960 (opens PubMed)
DGrade DOxidized LDL and isoprostanes (oxidative-stress markers)Oxidative stressLower oxidation markers vs baselineRCT
n 42 · 2015
Improved Oxidized LDL and urinary F2-isoprostanes fell from baseline after 4 weeks; blood pressure, body measures and lipids did not change, and differences were gone 40 days after stopping.
- Design
- RCT, n = 42, 2015
- Population
- Healthy, overweight and smoking adults aged 45 to 65
- Form
- Delphinol maqui extract
- Dose
- Extract with 162 mg anthocyanins, given 3 times daily
- Duration
- 4 weeks
- Source
- Reference 7 · PubMed 26400431 (opens PubMed)
DGrade DHbA1c and blood lipids in early prediabetesBlood sugarLower HbA1c, no control groupOpen-label trial
n 31 · 2016
Improved HbA1c fell from 5.65% to 5.35% (P = 0.003) and LDL fell (P = 0.001) while HDL rose; fasting glucose, insulin and glucose-tolerance tests did not change significantly.
- Design
- Open-label trial, n = 31, 2016
- Population
- Adults with newly diagnosed moderate glucose intolerance
- Form
- Delphinol
- Dose
- 180 mg each morning
- Duration
- 3 months
- Source
- Reference 6 · PubMed 27820958 (opens PubMed)
DGrade DHeart rate variability and stress resilienceStressMixed, small changesRCT
n 30 · 2023
Mixed Heart rate variability measures rose in the maqui group and fell in controls, and the SF-12 mental score improved; blood tests, blood pressure and body composition did not differ; the authors say unusually hot weather likely biased results.
- Design
- RCT, n = 30, 2023
- Population
- Healthy adults (15 per group)
- Form
- Maqui-based nutraceutical (Maqui 500)
- Dose
- 1,000 mg a day
- Duration
- 30 days
- Source
- Reference 8 · PubMed 36420523 (opens PubMed)
DGrade DSigns, symptoms and tear inflammation in dry eye diseaseDry eyesFewer symptoms, more tearsRCT
n 20 · 2023
Improved The symptom score (OSDI) fell and Schirmer test rose vs placebo (p < 0.05); tear break-up time and corneal staining did not change. Tear IL-1β, IL-6, IL-17A, TNFα and MMP9 fell.
- Design
- RCT, n = 20, 2023
- Population
- Patients with dry eye disease at an eye hospital in Bengaluru, India
- Form
- Maqui berry extract
- Dose
- Dose not stated in the abstract
- Duration
- 2 months
- Source
- Reference 4 · PubMed 37026311 (opens PubMed)
DGrade DTear volume and dry-eye quality of lifeDry eyesMore tearsOpen-label trial
n 13 · 2014
Improved Schirmer scores rose from 16.3 to 24.4 mm (30 mg) and from 18.7 to 27.6 mm (60 mg) after 30 days, and dry-eye quality-of-life scores improved in both groups.
- Design
- Open-label trial, n = 13, 2014
- Population
- Healthy volunteers with moderately dry eyes
- Form
- MaquiBright standardized extract
- Dose
- 30 mg or 60 mg a day
- Duration
- 60 days
- Source
- Reference 3 · PubMed 25208615 (opens PubMed)
DGrade DAfter-meal blood sugar in impaired glucose regulationBlood sugarLower after-meal glucoseCrossover RCT
n 10 · 2014
Improved Delphinol before rice lowered after-meal blood glucose and insulin compared with placebo.
- Design
- Crossover RCT, n = 10, 2014
- Population
- Volunteers with moderate glucose intolerance
- Form
- Delphinol (standardized to at least 25% delphinidins)
- Dose
- Single dose before a rice meal (amount not stated in the abstract)
- Duration
- Single test meals
- Source
- Reference 5 · PubMed 24861886 (opens PubMed)
What the numbers add up to
Each point is worked out from the data and the sources numbered on this page, with the arithmetic shown under it. It adds no new data and is not medical advice.
Eyes have the best data
Blood-sugar claims rest on small or uncontrolled studies
Studied doses
Doses used in research, shown against the official limits. They describe the studies, not a recommendation for you.
Studied doses in research, not advice. These are amounts used in research, not personal advice. Your clinician or pharmacist can say what fits you.
Doses studied in human trials
Interactions and safety
Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.
Interactions
0 agentsNone found in our sources.
Check with what you take
Kept on this device onlyAdd what you take. We list every interaction our evidence profiles cite between Maqui Berry and your picks, and between your picks.
- Loading names…
Add a supplement or medicine you take to check it against Maqui Berry.
Starting from one medicine? The interaction checker rates how serious each pair is, on a curated list of 19 entries for 11 medicines. This cabinet has no severity rating: it lists every interaction row our supplement pages cite.
Who should be careful
2 groups- Pregnancy, breastfeeding and children
- NCCIH notes that many dietary supplements have not been tested in pregnant women, nursing mothers or children.1
- Medicines and surgery
- No published drug or supplement interaction for maqui was found, so interaction data are limited rather than reassuring. NCCIH advises that supplements may interact with medications or pose risks before surgery, and to tell your health care providers about everything you use.1
How to read the label
What to check on the Supplement Facts panel.
How to read the label
1 checksWhere to buy Maqui Berry
Products from brands we partner with that contain Maqui Berry. Check the amount per serving against the doses studied above, and the label for other ingredients.
Maqui Berry products from partner brands
1 product Paid links · we earn a commission- Quick pickHerbsProLife Extension Tear Support with MaquiBright, 60 mg, 30 Veg Caps
1 capsule: 60 mg MaquiBright maqui berry extract, the dose used in the 74-person dry-eye trial
$13.50one-timeChecked Oct 15, 2026
Frequently asked questions
Short answers to common questions; the numbers link to the sources below.
Common questions
5 answersDoes maqui berry help dry eyes?
Does maqui berry lower blood sugar?
Is maqui berry safe?
How much maqui was studied?
Sources
9 sources: trial abstracts, NIH fact sheets and reference databases. Numbers in the text link here.
Sources cited on this page
9 sources- 1Using Dietary Supplements WiselyFact sheet National Center for Complementary and Integrative Health (NCCIH), 2019 · nccih.nih.gov
- 2Effects of MaquiBright(®) on improving eye dryness and fatigue in humans: A randomized, double-blind, placebo-controlled trial.RCT J Tradit Complement Med, 2019 · PMID 31193920
- 3MaquiBright™ standardized maqui berry extract significantly increases tear fluid production and ameliorates dry eye-related symptoms in a clinical pilot trial.Open-label trial Panminerva Med, 2014 · PMID 25208615
- 4Effect of maqui-berry extract in dry eye disease - A clinical and molecular analysis.RCT Indian J Ophthalmol, 2023 · PMID 37026311
- 5Delphinol® standardized maqui berry extract reduces postprandial blood glucose increase in individuals with impaired glucose regulation by novel mechanism of sodium glucose cotransporter inhibition.Crossover RCT Panminerva Med, 2014 · PMID 24861886
- 6Delphinol® standardized maqui berry extract significantly lowers blood glucose and improves blood lipid profile in prediabetic individuals in three-month clinical trial.Open-label trial Panminerva Med, 2016 · PMID 27820958
- 7A Randomized Clinical Trial Evaluating the Efficacy of an Anthocyanin-Maqui Berry Extract (Delphinol®) on Oxidative Stress Biomarkers.RCT J Am Coll Nutr, 2015 · PMID 26400431
- 8Short-term effects of a maqui-based nutraceutical on heart rate variability, psycho-physical resilience and on a few metabolic biomarkers: a randomized controlled study.RCT J Complement Integr Med, 2023 · PMID 36420523
- 9Clinical Evidence on the Health Effects of Aristotelia chilensis (Maqui Berry) Supplementation: A Systematic Review of Human Trials.Systematic review Antioxidants (Basel), 2026 · PMID 42351960
What changed
Every dated change to this page: what changed, who made it and why.
Change log
2 entries| Date | Change | Who and why |
|---|---|---|
| who should be careful | Stated that no published maqui interaction was found (interaction data limited). PubMed search 2023–2026 found no human trial newer than the 2026 systematic review already cited (PMID 42351960); the evidence table is unchanged. | Writer: Kymata Health EditorialTrigger: A–Z page audit |
| all | Initial editorial evidence review. Every PMID checked against NCBI E-utilities esummary (title, year, journal; none retracted) and each cited abstract read; numbers taken from the abstracts (full text or registry used only where noted). Funding disclosed per study: Oryza Oil & Fat Chemical, Anklam Extrakt and Maqui New Life (2019 MaquiBright trial, full text); Oryza author (2014 pilot); no funding (2023 India trial, full text); CORFO with Agrijohnson authors (2026 review); the other abstracts name no funder (disclosed as not stated). No maqui-specific page exists on our approved safety sources, so safety rows use only NCCIH general supplement guidance. Where to buy: Life Extension Tear Support with MaquiBright (label checked 2026-10-15). | Writer: Kymata Health EditorialTrigger: new page |
Supplement & Nutrient Encyclopedia. Educational information only; it is not medical advice and does not replace a clinician. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Statements about supplements have not been evaluated by the FDA.